NOVABRIDGE BIOSCIENCES

NBPNASDAQ

🏆 #3851 by market capUS Equity

$1.38▲ $0.00 (+0.36%)

After hours · at close

🔔

Track NBP

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 0.4%

7d▼ 13.5%

14d▼ 13.8%

30d▼ 25.5%

ytd▼ 65.4%

1y▼ 59.7%

🏦Market Cap

$158M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Good

Trading Snapshot

Day Range: $1.37 – $1.38
52-Week Range: $1.32 – $6.79
Volume: $3.75B
Avg Volume: $3.24B
Shares Outstanding: 115.3M
Next Earnings: Oct 29, 2026

Fundamentals Snapshot

Annual Revenue: $12M
Last Q Revenue: $3M
P/E Ratio: -2.4
P/S Ratio: 0.0x
EPS (TTM): $-0.42
Dividend Yield: 0.00%
Dilution (1yr): −38.4%

Why Investors Own NBP

✓High-growth profile — revenue up +21.1% YoY with expanding US Equity exposure.
✓Healthy economics — 44% gross margin and 20% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NOVABRIDGE BIOSCIENCES

NBP

Financial Trends

Revenue

$0▲ +0.0% YoY

Gross Margin

100.0%▲ +0.0% YoY

Operating Income

−$13M▼ −96.4% YoY

Free Cash Flow

−$21M▼ −94.6% YoY

Shares Outstanding

50.2M▼ −38.4% YoY

Net Cash

$30M▼ −$440M YoY

StockOtter · stockotter.space

About NOVABRIDGE BIOSCIENCES

NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.

🦦